External reports (aggregated public sources), Value Investors Club

Value Investors Club

Value Investors Club (.com) is an exclusive online investment club where top investors share their best ideas. Content available at the above link/PDF preview is an external article authored by a third party outside the Smartkarma network and has been aggregated by an online aggregator through publicly available sources and is displayed by Smartkarma in this format for user's convenience and general informational purposes only. Content does not constitute investment or financial advice and Smartkarma makes no representation or warranty regarding its accuracy or contents. Original third party author retains all copyright and other proprietary rights in the content. Access or use of third party links not controlled by Smartkarma are at the user's own risk.

External reports (aggregated public sources)

Equity Bottom-Up

<ul><li>Positive results from a Phase 3 clinical trial show that avasopasem reduces the severity of symptomatic oral mucositis (SOM) and decreases the need for opioid analgesics.</li><li>Galera Therapeutics plans to submit a New Drug Application (NDA) to the FDA based on these promising results.</li><li>There is potential for avasopasem to become a new standard of care for patients receiving radiation therapy for head and neck cancer.</li></ul><p><em>This content is sourced through publicly available sources and has been machine generated. Information displayed is for general informational purposes only. This article was originally published 3 months ago on Value Investors Club.</em></p>

Positive results from a Phase 3 clinical trial show that avasopasem reduces the severity of symptomatic oral mucositis (SOM) and decreases the need for opioid analgesics.Galera Therapeutics plans to submit a New Drug Application (NDA) to the FDA based on these promising results.There is potential for avasopasem to become a new standard of care for patients receiving radiation therapy for head and neck cancer.This content is sourced through publicly available sources and has been machine generated. Information displayed is for general informational purposes only. This article was originally published 3 months ago on Value Investors Club.

Galera Therapeutics Inc (GRTX) - Saturday, Jul 13, 2024